{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T23:05:07Z","timestamp":1792623907691,"version":"4.5.0"},"reference-count":47,"publisher":"Informa UK Limited","issue":"3","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2021,2,11]]},"DOI":"10.1080\/14656566.2020.1840552","type":"journal-article","created":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T15:26:13Z","timestamp":1603380373000},"page":"265-271","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":9,"title":["An evaluation of meropenem\/vaborbactam for the treatment of nosocomial pneumonia"],"prefix":"10.1080","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2366-6860","authenticated-orcid":false,"given":"Lauren M.","family":"Groft","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice and Science, PGY2 Infectious Diseases Pharmacy Resident University of Maryland School of Pharmacy,St. Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly C.","family":"Claeys","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Science, Assistant Professor, University of Maryland School of Pharmacy 20 N Pine St. Baltimore, MD,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily L.","family":"Heil","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Science, Associate Professor, University of Maryland School of Pharmacy 20 N Pine St. Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2020,11,2]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S177247"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1086\/653053"},{"key":"cit0003","unstructured":"CDC\u2019s Antibiotic-Resistant Germs: New Threats. Centers for disease control and prevention. Atlanta, GA: 2020. Available at: https:\/\/www.cdc.gov\/drugresistance\/biggest-threats.html [Last accessed 2020 Jul 30]"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw353"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01443-17"},{"key":"cit0006","unstructured":"Lee Y, Kim J, Trinh S. Meropenem\u2013vaborbactam (vabomereTM): another option for carbapenem-resistant enterobacteriaceae. P T. 2019;44(3):110\u2013113."},{"key":"cit0007","unstructured":"US Food and Drug Administration. Drug approval package. Avycaz\u00ae (ceftazidime\/avibactam) intravenous injection. 2015. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/206494s005,s006lbl.pdf [Last accessed 2020 Jul 30]."},{"key":"cit0008","unstructured":"US Food and Drug Administration. Drug approval package. Vabomere\u00ae (meropenem\/vaborbactam) intravenous injection. 2017. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209776lbl.pdf [Last accessed 2020 Jul 30]."},{"key":"cit0009","unstructured":"US Food and Drug Administration. Drug approval package. RecarbrioTM (imipenem, cilastatin, relebactam) intravenous injection. 2019. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/212819s000lbl.pdf [Last accessed 2020 Jul 30]."},{"key":"cit0010","unstructured":"US Food and Drug Administration. Drug approval package. Zerbaxa\u00ae (ceftolozane\/tazobactam) intravenous injection. 2014. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/206829lbl.pdf [Last accessed 2020 Jul 30]."},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw243"},{"key":"cit0012","first-page":"61(8):e00883\u201317","author":"Shields RK","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix783"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw636"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30747-8"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx139"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00633-16"},{"key":"cit0018","unstructured":"US Food and Drug Administration. Drug approval package. ZemdriTM (plazomicin) intravenous injection. 2018. Available from https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/210303orig1s000lbl.pdf [Last accessed 2020 Oct 13]."},{"key":"cit0019","unstructured":"US Food and Drug Administration. Drug approval package. Fetroja\u00ae (cefiderocol) intravenous injection. 2019. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/209445s000lbl.pdf [Last accessed 2020 Oct 13]."},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801467"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30554-1"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30731-3"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30796-9"},{"key":"cit0024","first-page":"41","volume-title":"Mandell, Douglas, and Bennett\u2019s principles and practice of infectious diseases","author":"Doi Y","year":"2020"},{"key":"cit0025","first-page":"62(4):e02228\u201317","author":"Rubino CM","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00568-16"},{"key":"cit0027","author":"Grande Roche KK","year":"2017","journal-title":"Center Drug Evaluation Res"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1086\/653057"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01713-15"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1136\/thx.49.2.104"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2092"},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00037-09"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/31.suppl_A.9"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00574-09"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00181-19"},{"key":"cit0036","first-page":"61(9):e00567\u201317","author":"Castanheira M","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00711-16"},{"issue":"1","key":"cit0038","doi-asserted-by":"crossref","first-page":"e01904","DOI":"10.1128\/AAC.01904-17","volume":"62","author":"Hackel MA","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00843-15"},{"key":"cit0040","volume-title":"Performance standards for antimicrobial susceptibility testing 27th information supplement. CLSI document M100-S27","author":"CLSI","year":"2017"},{"key":"cit0041","volume-title":"Breakpoint tables for interpretation of MICs and zone diameters. Version 10.0. V\u00e4xj\u00f6, Sweden: European Committee on Antimicrobial Susceptibility Testing","author":"EUCAST","year":"2020"},{"key":"cit0042","doi-asserted-by":"crossref","volume-title":"Comparative in vitro activity of meropenem\/vaborbactam and meropenem against a collection of real-world isolates of pseudomonas aeruginosa","author":"Patel T","DOI":"10.1093\/ofid\/ofz360.590"},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.0438"},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-018-0214-1"},{"key":"cit0045","first-page":"64(5):e02313\u201319","author":"Ackley R","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa051"},{"key":"cit0047","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz1131"}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2020.1840552","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T18:00:32Z","timestamp":1623088832000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14656566.2020.1840552"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,2]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,2,11]]}},"alternative-id":["10.1080\/14656566.2020.1840552"],"URL":"https:\/\/doi.org\/10.1080\/14656566.2020.1840552","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-09-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}